

# MSTS Newsletter

Volume 19, Winter 2017

## Inside this Issue

President's Report . . . . . 1	Fellowship Committee . . . . . 5	2017 Annual Meeting Program Committee . . . . . 8
MSTS Executive Committee . . . . . 1	Membership Committee . . . . . 5	Thank You 2016 Annual Meeting Supporters and Exhibitors . . . . . 8
Treasurer's Report . . . . . 2	Education Committee . . . . . 6	
2016 MSTS Annual Meeting Report . . 3	Practice Management Committee. . . 6	
2017 Specialty Day . . . . . 3	Evidenced Based Medicine Committee. . . . . 6	
Research Committee . . . . . 4		

## President's Report - Robert H. Quinn, MD


Happy New Year! 2017 looks to be another promising year for the Musculoskeletal Tumor Society (MSTS). I wish to thank Ted Parsons for his terrific leadership and dedication to the Society. I would also like to thank Kristy Weber for her time and dedication to the Society and Executive Committee over the past six years and to congratulate her on being nominated to the American Academy of Orthopaedic Surgeons (AAOS) Presidential Line.

We had a very successful meeting in Detroit and I would like to congratulate Michael Mott for an extraordinary effort

as well as the rest of the Annual Meeting Program Committee (Ted Parsons, John Abraham, Alexandre Arkader, Parker Gibbs, David Greenberg, Patrick Lin, and Kevin Raskin).

The MSTS Executive Committee welcomes Joel Mayerson who enters the Presidential Line as our new Treasurer, Francis Hornicek as our new Member-at-Large, and Kevin Raskin as the Program Chair for our 2017 Annual Meeting. More to come on what we believe will be a great Annual Meeting in Denver, September 27-29, 2017.

*Continued on page 2*



## MSTS Executive Committee

### President

Robert H. Quinn, MD  
quinnr@uthscsa.edu

### President-Elect

Joseph Benevenia, MD  
benevejo@rutgers.edu

### Secretary

R. Lor Randall, MD, FACS  
r.lor.randall@hci.utah.edu

### Treasurer

Joel Mayerson, MD  
joel.mayerson@osumc.edu

### Immediate Past President

Theodore W. Parsons III, MD, FACS  
tparson3@hfhs.org

### Past President

Richard M. Terek, MD, FACS  
richard\_terek@brown.edu

### Education Committee

Carol D. Morris, MD  
cmorri61@jhmi.edu

### Research Committee

Michelle A. Ghert, MD, FRCS  
ghert@hhsc.ca

### Membership Committee

Michael P. Mott, MD  
mmott2@hfhs.org

### Members-at-Large

Lee Leddy, MD  
leddyj@musc.edu

Francis Hornicek, MD  
fhornicek@partners.org

### MSTS Headquarters

9400 W. Higgins Rd., Suite 500 Rosemont, IL 60018 info@msts.org 847/698-1625 fax: 847/268-9574

## Treasurer's Report

- Joel Mayerson, MD

We had a very successful Annual Meeting in Detroit which increased our financial reserves to just over \$1 million. Our past financial success has allowed the Society to be able to fund three research grants partnering with the Musculoskeletal Transplant Foundation (MTF), AAOS, and OREF while remaining financially sound. The overall financial status of the MSTs continues to be secure (details were presented at our Annual Meeting this past fall and will again be presented at Specialty Day in March).

The Finance Committee held its quarterly meeting this past fall. The Finance Committee reviewed our investment partner, Charles Schwab, and felt we were not getting enough value for the advisory fees we were paying them. With the assistance of the AAOS support staff, the committee interviewed several companies to see if we could get improved value with respect to investing advice as well as maintaining low-cost fees. The committee decided that Morgan Stanley provided the best value and recommended that the Society's assets be switched from Charles Schwab to Morgan Stanley. This change was approved at the November Executive Committee Meeting. We are currently completing the transfer of funds to Morgan Stanley.

Thank you to all members of the Finance Committee and the AAOS support staff, most especially the MSTs's Financial Director, Anna Greene, for all of her guidance through this process. Please do not hesitate to contact me with any questions or concerns. I am looking forward to seeing all of you at Specialty Day in San Diego.

### 2017 Dues Renewal

Friendly Reminder – Please submit payment for your 2017 membership dues. Pay your 2017 Membership Dues [online](#).

Forgot your login information? Contact MSTs for assistance at 847/698-1625 or [info@msts.org](mailto:info@msts.org).

## President's Report, cont'd from pg. 1

Under the leadership of Carol Morris, Chair of the Education Committee, our online musculoskeletal oncology course, a joint venture between the AAOS and MSTs is currently under development. This has the potential to provide not only wide exposure for the society, but an income stream as well. There is a lot of work to be done, and it provides great opportunity for many of our members to participate.

Thanks to the work initiated during the last couple of years, we have significant research dollars available for our members (annual grant opportunities) as a result of collaboration with the Orthopaedic Research and Education Foundation (OREF) and MSTs. The MSTs Research Committee, chaired by Michelle Ghert, has been busy reviewing the submissions. These funding partnerships are truly significant additions to our research opportunities as a society. Please consider supporting both the MSTs and the OREF and for those of you who have done so, thank you!

A big "Thank You" to Michelle Ghert for organizing the effort *Moving Forward through Consensus – A Modified Delphi Approach to Determine Top Research Priorities in the Field of Musculoskeletal Oncology*. Thank you also to all of the 44 participants who made this effort successful. The meeting took place following the Annual Meeting in Detroit and has generated a report which will prove very helpful to the Society and its mission to support research.

Under the leadership of Ben Miller,

Chair of the Evidence Based Medicine Committee, we are aggressively investigating the potential for an MSTs Registry. A MSTs Registry Workgroup made up of 16 active and candidate MSTs members and co-chaired by Ben Miller and George Calvert, has been working diligently to explore options and we expect to interview potential vendors during the AAOS meeting.

The Executive Committee, during Kristy Weber's term as President, initiated a strategic planning process in 2013 which resulted in the *MSTs Strategic Plan 2014 – 2017* as well as new vision and mission statements. Now that 2017 is upon us, we will be creating a new 3-year Strategic Plan in the year to come. The process will begin with a new member survey this spring, so please stay tuned and participate in the process.

The Society and all of the committees are extremely active these days and improving the MSTs at a greater pace than ever. It is the membership and your involvement, hard work, and meaningful feedback that make this all possible. If you have thoughts and ideas that you want to share, please feel free to reach out. We are making every effort to be open and transparent with the membership, and we welcome your comments and participation.

I look forward to serving you this year, and I am committed to following in the footsteps of my predecessors, and helping to ensure another year of success.

**I look forward to seeing you in San Diego!**



# 2016 MSTs Annual Meeting Report



The 2016 MSTs Annual Meeting was held October 5-7, 2016 in Detroit, Michigan, affectionately referred to by the locals as the “D” at the Detroit Marriott Hotel at the Renaissance Center. Over 250 health professionals registered to attend informative and interesting sessions. The Annual Meeting Program Committee was pleased to see so many active members in attendance. This year, the meeting offered an ICD-10 coding course specifically geared toward Musculoskeletal Tumor Oncology and held an interactive Nurse and Allied Health Professionals course.

Socially, our meeting kicked off on Wednesday, October 5<sup>th</sup> with a Welcome Reception on Detroit’s international waterfront which offered beautiful panoramic views of Detroit and Windsor, Canada giving our opening meet and greet a true international flavor. On the morning of Thursday, October 6<sup>th</sup>, early birds participated in the MSTs Fun Run 5k along the restyled Detroit Riverwalk kicking off a day full of informative and engaging podium presentations.

Attendees had the opportunity to hear interesting and provocative data during poster presentations where authors showcased their work and facilitated open dialogue with their colleagues. The



opportunities for scientific and social networking was outstanding.

On Thursday evening, participants enjoyed the MSTs signature dinner and live entertainment at the highly regarded The Henry Ford Museum. Attendees

enjoyed an eclectic menu and had full access to roam the museum’s 12 acres while exploring an unparalleled collection of awe inspiring artifacts.



On Friday, October 7<sup>th</sup>, the presidential guest speaker, Kaled M. Alektiar, MD, FASTRO, a distinguished Radiation Oncologist from Memorial Sloan Kettering in New York, offered members additional perspective and insight on the management of sarcomas.

While exploring the exhibit hall, attendees visited the MSTs Product Theater for a unique way to interact with exhibitors and learn about new products and technologies.

A special thanks to everyone who participated in the success of this meeting!

In particular we would like to highlight the contributions of our presenters, generous sponsors and exhibitors, the MSTs Executive Committee and the MSTs Annual Meeting Program Committee for their efforts in making this conference successful.

We look forward to seeing you at the next MSTs Annual Meeting, September 27-29, 2017 in Denver, Colorado!

# 2017 MSTs Specialty Day – Joel Mayerson, MD, Chair

The AAOS Annual Meeting is nearly upon us. We would like to encourage all members to attend MSTs Specialty Day on **Saturday, March 18, 2017**. This year’s program will continue to utilize interactive segments to encourage active audience participation. In addition, we will again be setting aside time for members to present new ideas for translational research projects that might be pursued on a cooperative, multi-institutional basis by members of the Society. We will again try to encourage member participation during the business meeting with an “open mic” session as time allows. This time for members to speak has provided the opportunity for informative and stimulating idea sharing. We are continuing to try to bring novel ideas and topics to engage our Society members with the highlights being sessions on: translational advances in sarcoma care, methods to improve practice management, a research forum, and an interactive session that will help all members both newly minted and mature address challenges in their practice. Lastly, we will finish the day with a forum that will help us engage our youngest members and continue the vitality of the MSTs into the future. We look forward to seeing you at Specialty Day in March.

## Specialty Day Research Forum

We are again having an open forum that will allow time for members to discuss research ideas with the aim of facilitating multi-institutional and/or collaborative research among members of our Society. This session will occur from 11:35 AM until 12 Noon at Specialty Day on Saturday March 18 and will be moderated by past MSTs president, Dr. Ed Cheng. Please send your ideas for consideration to [Joel.Mayerson@osumc.edu](mailto:Joel.Mayerson@osumc.edu) by Friday, February 10<sup>th</sup>. The Specialty Day Committee will try to accommodate as many projects as time will allow that meet the spirit of facilitating multi-institutional and/or collaborative research. Please don’t hesitate to contact members of the committee Joel Mayerson ([Joel.Mayerson@ousmc.edu](mailto:Joel.Mayerson@ousmc.edu)), Wakenda Tyler ([Wakenda\\_Tyler@urmc.rochester.edu](mailto:Wakenda_Tyler@urmc.rochester.edu)), or Megan Anderson ([manders6@bidmc.harvard.edu](mailto:manders6@bidmc.harvard.edu)) with any questions. We look forward to seeing your exciting new research ideas.

## Research Committee

– Michelle Ghert, MD, FRCSC, Chair

The MSTs is very happy to provide information on an abundance of opportunities for research funding, career development and collaboration available to the MSTs Membership. For any questions, please contact Michelle Ghert at [ghert@hhsc.ca](mailto:ghert@hhsc.ca).

### FUNDING OPPORTUNITIES

#### Sarcoma Strong Research Science Grant

This new funding opportunity is directed at basic science research in the study of sarcoma. Matt DiCaprio raised funds through two annual running events in Albany, NY with the goal of supporting scientific research in the field of sarcoma biology and treatment. The projected due date for applications will be May 1, 2017. Further details regarding the RFA will be available shortly.

#### OREF/MSTs Clinical Research Grant in Orthopaedic Oncology

A call for proposals for the [2017 OREF/MSTs Research Grant](#) is posted. Information regarding this grant is as follows:

##### Who Applies?

- PI or Co-PI must be an orthopaedic surgeon.
- PhDs and DVMs are eligible if affiliated with an orthopaedic department and working with an orthopaedic surgeon.
- PI or Co-PI must be an MSTs member in good standing.

Applications and more information is available on the OREF and MSTs websites. <http://www.oref.org/oncologygrant>  
Deadline: February 20, 2017  
Funding available: \$100,250 over 2 years  
Funding start date: July 1, 2017

### CAREER DEVELOPMENT OPPORTUNITIES

#### AAOS/OREF/ORS Clinical Scholar Career Development Program

The 2017 AAOS/OREF/ORS Clinician Scholar Career Development Program (CSDP) will be September 21-23, 2017 in Rosemont, Illinois. The program is open to residents, fellows, and junior faculty. The AAOS selects applicants and the MSTs will support ONE of our members who qualify to attend with priority given to fellows and

junior faculty. Our rationale is to cultivate talented individuals who will go on to submit clinical trials to the MSTs or be involved in other scholarly and leadership activities. Applications are due March 31, 2017.

For more information visit: [www.aaos.org/csdp](http://www.aaos.org/csdp)

The MSTs would like to thank Dr. Alexander Christ and Dr. Brian Walczak for their participation in the 2016 CSDP!

#### MSTs Sponsoring Member to Attend PPCR Course

To all MSTs members interested in learning the methodological concepts of clinical research:

The MSTs is pleased to announce the sponsorship of one member to attend the 11th Annual Principles and Practice of Clinical Research (PPCR) course. This course will be held at the end of September 2017 at the Ron Joyce Business Centre in Burlington, Ontario, Canada. This course will provide participants with practical knowledge in current research principles that are fundamental, if not necessary in today's world of clinical research. The interactive learning environment will allow participants to interact with renowned clinical researchers and gain invaluable insight into what makes a successful research study. The PPCR course will provide participants with a comprehensive foundation in the present state of health research methodology by covering evidence based-medicine principles, levels of evidence, research ethics, funding opportunities, as well as data management and budgeting.

The MSTs would like to thank Dr. Daniel Lerman for his attendance at the 2016 PPCR Course.

Further details of the course are available in the following link:

<http://www.cmecourses.ca/courses/id/5>

All interested members are requested to submit a cover letter stating the reasons for interest in the course and the type of research study to be developed, as well as a current CV to [info@msts.org](mailto:info@msts.org) by August 15, 2017.

#### ORS/OREF Grant Writing Course Saturday March 18, 2017 8:00 AM - 5:00 PM Hilton Bayfront Hotel San Diego, CA

This popular introductory course is the first in a sequence of opportunities offered by the ORS and OREF for new investigators to learn the art of grant writing. This course is ideal for investigators who are in the process of writing their first grant proposals. Experts will offer strategies for writing a compelling Aims page, developing a strong approach to test an exciting hypothesis, and using preliminary data and supporting documents to present a cohesive final grant proposal. A mock study section provides a first-hand look at what is involved in NIH peer review. Lunch and a post-course networking reception are included in the registration fee. Pre-registration required (\$175).

For more information, visit: <http://www.ors.org/2017-orsoref-grant-writing-course>

#### ORS/OREF/AAOS New Investigator Workshop: Clinical, Translational and Basic Science Workshop April 28-29, 2017 Baltimore, MD

Grant writing is an important and essential skill in order to achieve a successful career in academia and as an investigator. As part of their commitment to those in the field of musculoskeletal research, the ORS, OREF, and AAOS have partnered for more than 20 years to provide our orthopaedic research community of residents, surgeons, basic scientists, and engineers with the opportunity to learn the necessary skills to reach that milestone and write a successful grant application.

To date, past attendees have received more than \$85M from NIH alone.

Faculty will offer practical insights on designing impactful basic, translational, and clinical grant proposals and how to effectively communicate significance and innovation.

The Grant Writing Workshop features: Mock Study Section where faculty will review provisional grants provided by the registrants.

Specific Aims Lab which will allow attendees to collaborate with faculty and peers to revise and improve the specific aims section of the grant application. The key component to the grant proposal.

## Membership Committee - Michael Mott, MD, Chair

The Membership Committee is here to serve you! If you have any ideas which you feel can improve the membership experience please feel free to contact the chair or any membership committee member at any time.

It has now been just about six months since we have launched the MSTs forMD community. for[MD] is our online interchange for more immediate membership sharing of ideas, cases and membership interaction. Half of MSTs members have already joined the community, and there have been 25 unique discussions to date. The link to access MSTs' private community on for[MD] is: <https://formd.com/group/4319>

Login consists of your email address and your for[MD] password. If you have forgotten your password, then please go to the following link and follow the instructions. This will generate an email to reset your password: <https://formd.com/forgot-password>

If you have never logged in before, you must activate your account. You can do this by requesting your invitation code by emailing [info@formd.com](mailto:info@formd.com) We welcome your participation in this platform.

The Membership Committee would like to welcome the following new members who were recently approved as full members by the action of the Executive Committee:

**Abdulrahman Mohammed Alaseem, MD**  
- Resident

**Tessa Balach, MD** – Active

**Manpreet (Meena) Bedi, MD** – Affiliate

**Alexandra K. Callan, MD** – Candidate

**Cynthia L. Emory, MD** – Fellow

**Kenneth R. Gundle, MD** – Candidate

**Donald A. Hackbarth, MD** – Active

**Sean P. Kelly, MD** – Resident

**Kevin MacDonald, MD** – Active

**Nicole I. Montgomery, MD** – Candidate

**John C. Neilson, MD** – Active

**Dipak B. Ramkumar** – Resident

**Geoffrey William Siegel, MD** – Candidate

**Phillip Alexander Taylor, MD** – Candidate

**Robert Jewell Wilson, II, MD** – Candidate

Encourage your colleagues to join MSTs. Learn more by visiting the [MSTs](http://MSTs) website.

**CERAMENT™ BONE VOID FILLER**

# Don't just fill a void. Remodel it.

Unicameral cyst in a twelve-year-old girl demonstrates complete bone remodeling with CERAMENT™ BONE VOID FILLER.

**Pre-op**  
Immediate post-op CERAMENT™ BONE VOID FILLER is highly visible under fluoroscopy. Note only partial fill of defect.

**12 months post-op**  
shows transformation of CERAMENT™ BONE VOID FILLER into bone

- COMPLETE BONE REMODELING IN 12 MONTHS\*
- HIGHLY INJECTABLE THROUGH A 16G NEEDLE
- ENHANCED RADIOPACITY

Visit us at MSTs to learn more.

1. Complete twelve-month bone remodeling with a bi-phasic injectable bone graft substitute in the minimally invasive treatment of benign bone tumors. CERAMENT™ BONE VOID FILLER. White Paper Authored by Kaczmarczyk J. & Sowinski P. Department of Orthopedics and Traumatology, Poznań University of Medical Sciences, Poland | Images reproduced with permission of J. Kaczmarczyk and P. Sowinski.

CERAMENT is a trademark of BONESUPPORT AB. Zimmer Biomet is the exclusive distributor of CERAMENT in the U.S. | PR 0556-01 en US.

**BONESUPPORT™**

## Fellowship Committee - Joel Sorger, MD, Chair

Please visit the [Fellowship](#) pages of the MSTs web site for an updated list of all the MSTs Recognized Musculoskeletal Oncology Fellowships. Along with this list are the criteria that they have agreed to meet to be recognized. The rank list submission deadline for fellowship programs to the SF match is Tuesday, April 6th 2017. The results are released to the programs and applicants on Thursday, April 20th. Any vacancies which remain after the match will be announced on the Immediate Vacancies page. The Fellowship Match Committee of the Board of Specialty Societies is looking into the feasibility of a single match day for all

subspecialties. More information will be available after their meeting at the AAOS.

MSTs Musculoskeletal Tumor Society

Find a Doctor | Donate | Login

Home | About MSTs | Education and Meetings | Membership | Fellowships | Research | For The Patient

### Fellowships

Match Information

Omega Medical Grants

Habiter Fellowship

2013 Recipient Summary

**Fellowship Committee**

List of MSTs Recognized Fellowships

Criteria to Join MSTs

View the Curriculum Guidelines

View the MSTs Fellowship Surgical Guidelines (ABC Requirements)

Fellowship Match Timeline

2015 Annual Meeting

Support MSTs

For The Patient

Become a Member

Copyright © 2014 Musculoskeletal Tumor Society. MSTs. All rights reserved. | Terms of Use | About MSTs | Contact MSTs  
9400 W. Higgins Road, Suite 500 | Rosemont, IL 60018 | 847.498.1423 | [msts.org](http://msts.org)

## Education Committee

- Carol D. Morris, MD, Chair

---

### AAOS Annual Meeting

We have a busy Annual AAOS meeting ahead. We are offering 5 Tumor Instructional Course Lectures this year:

1. Soft Tissue Tumors,  
*Moderator: Val Lewis*
2. Common Bone Tumors and Reconstructive Options in pediatric and Young Adult Patients, *Moderator: Joel Sorger*
3. How to Approach and Treat Metastatic Disease-Interactive and Case-based Discussion,  
*Moderator: Val Lewis*
4. Sports Tumors- How to Manage Orthopaedic Conditions in the Setting of Benign Tumors,  
*Moderator: Wakenda Tyler*
5. Bone and Soft Tissue Tumors for the General Orthopaedic Surgeon: How to Avoid Errors,  
*Moderator: Carol Morris*

This year's Symposium is entitled Extreme Limb Salvage: Application of Oncologic Reconstructions for Oncologic and Non-Oncologic Indications moderated by Rich McGough. In addition, there are 2 scientific podium sessions and 2 Scientific Exhibits and 5 Video Theater presentations focusing on tumor-related topics. We hope our membership will show their support as active participants in all of our education sessions. As always, new education sessions will need to be submitted soon after the Annual Meeting is over. We encourage all members of the Society to submit their ideas. For those new to the process, the Education Committee is available to partner with you or provide guidance in putting a program and faculty together for an ICL or symposium.

### On-line Pathology Course

The Education Committee has been hard at work completing the on-line AAOS/ MSTS virtual musculoskeletal pathology course. The course covers General Tumor Principles, Benign Bone Tumors, Malignant Bone Tumors, Soft Tissue Tumors, and Metastatic Disease. Our goal is to have the course completed in time for graduating residents to use as a resource for board preparation. A tremendous amount of work has gone in to this effort. We are grateful for to all of the MSTS members that have contributed their time and expertise to making this course possible.

## MSTS Practice Management Committee

- John P. Heiner, MD, Chair

---

As of January 1<sup>st</sup> two codes used by the MSTS will change. 20240 and 20245 the superficial and deep bone biopsy codes were changed to zero day global codes and were surveyed several times over the past two years. 20245 came up on a CMS screen for the number of office visits for a ten day global code which is what lead to this change. After much discussion at the RUC (AMA Relative Value Committee) and with CMS they were accepted as zero day global codes and surveyed. The final values reflect what CMS thinks is the correct value after subtracting out the office visits and using the RUC surveys that many of you filled out. Both codes decreased in value due to the loss of the office visits. Orthopedics is the predominant user of 20245 while podiatry is the main user of 20240. We also changed the definition of what is a superficial (hands and feet) and a deep (long bones and pelvis) bone biopsy. You can check the new CPT book for the complete definitions. Remember that only the day of the biopsy is now included in the code so any additional work should be billed separately.

The segmental allograft codes are still at the AMA CPT group and will come for survey probably this spring. We will be the predominant group filling out the surveys. Many MSTS members have complained about not being able to bill the allograft portions of the case so hopefully this will help. Currently there are three codes up for discussion and all of the codes include fixation of the allograft unless CPT removes that portion of the code. If you are asked to fill out a survey please read the code descriptor carefully and include all time for sizing and shaping the graft as well as the fixation. These will probably be Z codes which are intra-operative codes only. They will always be billed with other 90 day global codes such as a radical resection code.

We are continuing to try to get ICD-10 changed to include more specificity in the soft tissue malignancies. So far that has been an uphill battle due to the pre-existing structure of ICD-10. The Center for Disease Control has been helpful but the WHO (World Health Organization) has not looked favorably on our ideas.

## Evidence Based Medicine Committee

- Ben Miller, MD, Chair

---

The EBM Committee is continuing to work on two projects jointly funded by the AAOS and MSTS. The first is a clinical practice guideline "The use of imaging prior to referral to a musculoskeletal oncologist," which is in the final stages of the systematic literature review. Second, Raj Rajani is the primary investigator on an appropriate use criteria "Surveillance of local recurrence and distant metastasis after surgical treatment of bone and soft tissue sarcoma," which is in the initial phases of design and planning. We will soon be asking for volunteers to be members of the writing or voting panel – please watch for this announcement and join this important effort!

Felasfa Wodajo is leading the group to create an information statement on inadvertent excisions of soft tissue sarcomas. Our hope is that this committee can periodically use literature summarization, expert opinion, and common sense to provide guidance and advice to all practitioners involved in particular aspects of the care of musculoskeletal neoplasia. Future topics include the evaluation of a destructive lesion of bone of unknown etiology and the treatment of metastatic disease of bone. We are always looking for new ideas, so please let us know if you have an idea for a topic in need of an information statement.

Eric Henderson is leading a working group formed to create an MSTS platform for prospective data collection of sarcoma patients. This is an incredibly exciting proposal, as the establishment of a registry designed to record the outcomes most important to our patients and members will be a valuable and consistent resource long into the future. Currently the group is narrowing down the field of potential vendors, and we hope to choose a finalist this spring. Within the next year we plan to create a vision for registry leadership and steering committees, finalize the scientific goals, and search for short- and long-term financial support.

Real Time Feedback from Faculty and NIH Officers  
Mentoring

For more information, visit: <http://www.ors.org/orsorefaaos-grant-writing>

### Young Investigators Initiative: Grant Mentoring and Career Development Program

The United States Bone and Joint Initiative (USBJI) is dedicated to raising public awareness and to increase the research of musculoskeletal diseases. The Young Investigator Initiative is a career development and grant-mentoring program that provides early-career investigators an opportunity to work with experienced researchers in our field to assist them in securing funding and other survival skills required for pursuing an academic career. This career development and grant mentoring program is open to promising junior faculty, senior fellows, or post-doctoral researchers nominated by their department or division chairs. It also is open to senior fellows or residents who are conducting research and have a faculty appointment in place or confirmed. Basic and clinical investigators, with or without training awards (including K Awards), are invited to apply. Investigators selected to take part in the program attend two workshops, 12-18 months apart, and work with faculty between workshops to develop their grant applications.

The application deadline is July 15<sup>th</sup> 2017, and the workshop is November 10-12, 2017 in Toronto, Ontario. The unique aspect of this program is the opportunity for attendees to maintain a relationship with a mentor until their application is funded. Application details can be found on the USBJI website at <https://www.usbji.org/programs/yii/call-for-applications>.

### OPPORTUNITIES FOR COLLABORATION

#### PARITY Trial Update

The Prophylactic Antibiotic Regimens in Tumor Surgery (PARITY) Trial has made outstanding progress this year. Several more US and international sites have joined the study, including those in Europe. The 200<sup>th</sup> patient was enrolled into PARITY in December 2016. This marks a critical milestone for this trial as the 600

patient enrolment target is now within feasible range. Several more clinical sites, including those in the United States and internationally, are in the start-up phase and are soon to join the PARITY team.

Congratulations to all PARITY Investigators and their research teams!!!

Please see [www.PARITYtrial.com](http://www.PARITYtrial.com) for further information. All MSTs members are invited to join this exciting international collaboration.

#### Local Bisphosphonate Effect on Recurrence in Extremity Giant Cell Tumor of Bone

A multi-center study comparing the local recurrence rate of primary extremity giant cell tumor of bone surgically treated with and without the addition of local bisphosphonate is ongoing. Currently 10 centers are enrolling patients. The hypothesis is that the local administration of bisphosphonate (zoledronic acid) will decrease the recurrence rate of GCT compared to aggressive intralesional curettage and traditional local adjuvants. All MSTs members are invited to join this collaboration.

Please contact Dr. David Greenberg at [dgreenb5@slu.edu](mailto:dgreenb5@slu.edu) if you are interested in participating in this study.

#### Consensus Project to Identify Research Priorities in Orthopaedic Oncology

In collaboration with the OREF and MSTs, we have completed a 3-phase modified Delphi process to determine research priorities in our field. A total of 80 participants were involved in the process. The final in-person meeting took

place on October 7, 2016 at the Detroit Marriott. The panel consisted of 37 in-person participants, including a patient representative, and 7 remote participants, accounting for participation from 12 countries around the world.

The final report is available. Please contact [schnep@mcmaster.ca](mailto:schnep@mcmaster.ca) if you are interested in receiving a pdf copy of the report. This final report is being prepared for peer-reviewed publication.

This competitively funded, scientific, multi-step, vetted and highly participated process identified the following 4 top research priorities/questions:

First Rank: Does less intensive surveillance of sarcoma patients affect survival?  
Methodology: Randomized Controlled Trial

Second Rank: What are the outcomes over time for orthopaedic oncology implants?  
Methodology: Prospective Registry

Third Rank: Does resection vs. stabilization improve oncologic outcomes in oligometastatic bone disease without compromising functional and surgical outcomes?  
Methodology: Randomized Controlled Trial

Fourth Rank: What is the natural history of untreated fibromatosis?  
Methodology: Prospective Cohort

The MSTs and the consensus working group members are inquiring into collaboration with the OREF, industry and the Desmoid Tumor Foundation to help develop protocols and identify funding opportunities for these research priorities. Stay tuned for developments!



Consensus project to identify research priorities in orthopaedic oncology final in-person meeting consisting of 37 in-person participants, including a patient representative, and 7 remote participants, accounting for participation from 12 countries around the world October 7, 2016 in Detroit, Michigan.

**Annual Meeting  
Program Committee**  
- Kevin Raskin, MD, Chair

Save the date for the MSTs 2017 Annual Meeting, September 27-29, 2017 in Denver, Colorado at the Grand Hyatt Denver. The meeting will kick-off with a welcome reception on Wednesday evening. Thursday will encompass a full day of educational programming and after making connections with colleagues, exploring new technologies/products in the exhibit hall, and learning from experts in the field, the meeting will adjourn on Friday afternoon. Abstracts will open for submission in early March – we look forward to your submission, and to seeing you in Denver!



SAVE THE DATE

**MSTS 2017 ANNUAL MEETING**  
**SEPTEMBER 27 - 29, 2017**

GRAND HYATT DENVER  
DENVER, COLORADO

**SINCERE APPRECIATION  
TO OUR 2016 ANNUAL MEETING**

**SILVER SUPPORTERS**

Onkos Surgical  
Stryker Orthopaedics  
Zimmer Biomet

and **EXHIBITORS**


Biocomposites, Inc.  
Bodycad  
BoneSupport  
CarboFix Orthopedics, Inc.  
DePuy Synthes  
Exactech, Inc.  
Implantcast  
LifeNet Health  
LinkBio Corp.  
Merete Technologies, Inc.  
Musculoskeletal Transplant Foundation  
Onkos Surgical  
Smith & Nephew, Inc.  
Stryker Orthopaedics  
Vector Surgical  
Wound Care Technologies, Inc.  
Wright Medical Technology  
Zimmer Biomet



2016

**ANNUAL MEETING**

**OCTOBER 5 - 7, 2016**



**Musculoskeletal Tumor Society**

9400 W. Higgins Road, Suite 500 • Rosemont, IL 60018

website: [www.MSTS.org](http://www.MSTS.org)

phone: 847/698-1625 fax: 847/268-9574 e-mail: [info@msts.org](mailto:info@msts.org)